Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study.

Marc Miravitlles, Antonio R Anzueto, Santiago Ewig, Delfino Legnani, Kathrin Stauch

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

OBJECTIVE: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin. METHODS: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients' daily lives. RESULTS: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7%) than GPs (15.5%). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days. CONCLUSIONS: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.

Original languageEnglish (US)
Pages (from-to)267-277
Number of pages11
JournalTherapeutic Advances in Respiratory Disease
Volume3
Issue number6
StatePublished - Dec 2009

Fingerprint

Chronic Bronchitis
Chronic Obstructive Pulmonary Disease
Spirometry
Therapeutics
History
Primary Health Care
Thorax
Smoking
Guidelines
Anti-Bacterial Agents
Physicians
moxifloxacin

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this

Characterisation of exacerbations of chronic bronchitis and COPD in Europe : the GIANT study. / Miravitlles, Marc; Anzueto, Antonio R; Ewig, Santiago; Legnani, Delfino; Stauch, Kathrin.

In: Therapeutic Advances in Respiratory Disease, Vol. 3, No. 6, 12.2009, p. 267-277.

Research output: Contribution to journalArticle

Miravitlles, Marc ; Anzueto, Antonio R ; Ewig, Santiago ; Legnani, Delfino ; Stauch, Kathrin. / Characterisation of exacerbations of chronic bronchitis and COPD in Europe : the GIANT study. In: Therapeutic Advances in Respiratory Disease. 2009 ; Vol. 3, No. 6. pp. 267-277.
@article{8e255104f652429c8eb02d6018685c2e,
title = "Characterisation of exacerbations of chronic bronchitis and COPD in Europe: the GIANT study.",
abstract = "OBJECTIVE: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin. METHODS: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients' daily lives. RESULTS: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7{\%}) than GPs (15.5{\%}). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days. CONCLUSIONS: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.",
author = "Marc Miravitlles and Anzueto, {Antonio R} and Santiago Ewig and Delfino Legnani and Kathrin Stauch",
year = "2009",
month = "12",
language = "English (US)",
volume = "3",
pages = "267--277",
journal = "Therapeutic Advances in Respiratory Disease",
issn = "1753-4658",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Characterisation of exacerbations of chronic bronchitis and COPD in Europe

T2 - the GIANT study.

AU - Miravitlles, Marc

AU - Anzueto, Antonio R

AU - Ewig, Santiago

AU - Legnani, Delfino

AU - Stauch, Kathrin

PY - 2009/12

Y1 - 2009/12

N2 - OBJECTIVE: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin. METHODS: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients' daily lives. RESULTS: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7%) than GPs (15.5%). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days. CONCLUSIONS: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.

AB - OBJECTIVE: The GIANT study collected information on patients with acute exacerbations of chronic bronchitis (AECB) and chronic obstructive pulmonary disease (COPD) and the effect of treatment with moxifloxacin. METHODS: AECB history, concomitant diseases, moxifloxacin treatment, concomitant medication, clinical symptoms and adverse events were recorded. A questionnaire at the end of treatment recorded the impact on patients' daily lives. RESULTS: Among 9225 patients from eight European countries, marked variation was seen in characteristics including age, smoking history and type of exacerbation. Spirometry use was more common among chest physicians (66.7%) than GPs (15.5%). Patients with Anthonisen type 1 and 2 exacerbations had more frequent exacerbations and these patients experienced a greater impact on daily activities compared with patients with type 3 episodes. Patient symptoms improved with moxifloxacin treatment after a mean (SD) of 3.4 (1.8) days, allowing return to normal daily activities after 5.4 (4.4) days and with full recovery taking 6.5 (3.1) days. CONCLUSIONS: Characteristics of patients with AECB and acute exacerbations of COPD differ among European countries. Spirometry is under-used, particularly in primary care and antibiotic treatment does not always follow current guidelines. Results confirm the efficacy of moxifloxacin in the treatment of AECB in real-life conditions.

UR - http://www.scopus.com/inward/record.url?scp=77449133105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449133105&partnerID=8YFLogxK

M3 - Article

C2 - 19880426

AN - SCOPUS:77449133105

VL - 3

SP - 267

EP - 277

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

SN - 1753-4658

IS - 6

ER -